Oscar Health Posts Record H1 Profit, Raises 2026 Outlook
OSCR has more than doubled off its 52-week low of $10.69.
Summary
Oscar Health delivered record first-half profitability, swinging to a Q2 profit with net income of $361.8M on $4.88B in revenue, compared to a year-ago loss. The medical loss ratio improved sharply to 79.2% from 91.1%, while the SG&A ratio fell to 14.2%. Full-year earnings from operations guidance was raised to $500M-$700M, up from $250M-$450M, with MLR and SG&A ratio targets also improved. This follows the co-founder CTO's move to an advisory role in June, but the strong operating metrics and raised outlook signal accelerating momentum in the individual market. The results far exceed the Q1 baseline and suggest the company is scaling profitably.
At the time of this announcement, OSCR was trading at $30.85 on NYSE in the Finance sector, with a market capitalization of approximately $8B. The 52-week trading range was $10.69 to $33.10. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: Dow Jones Newswires.